Is Harmony Biosciences Holdings, Inc. (HRMY) a Buy, Sell, or Hold?
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$34.81 USD
-$0.73 (-2.05%)
- Volume
- 938.75K
- Average Volume
- 819.33K
- Market Capitalization
- $2.02B
- P/E Ratio
- 13.81
- Dividend Yield
- 0.00%
- Price Target
- $46.00
- Year High
- $40.87
- Year Low
- $25.52
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.58
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
32
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
31
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
$ 6.9M
HRMY Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
HRMY Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Germano Geno J | director | 2026-05-14 | A-Award | 30.76 | 2026-05-18 |
| Germano Geno J | 2026-05-14 | 0 | 2026-05-18 | ||
| Szyper Linda M | director | 2026-05-14 | A-Award | 30.76 | 2026-05-18 |
| Philip Ron M | director | 2026-05-14 | A-Award | 30.76 | 2026-05-18 |
| Graf R. Mark | director | 2026-05-14 | A-Award | 30.76 | 2026-05-18 |
| Sabater Juan A. | director | 2026-05-14 | A-Award | 30.76 | 2026-05-18 |
| Sender Gary | director | 2026-05-14 | A-Award | 30.76 | 2026-05-18 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2026-05-01 | M-Exempt | 0 | 2026-05-18 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2026-05-01 | M-Exempt | 0 | 2026-05-18 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2026-05-01 | F-InKind | 31.83 | 2026-05-18 |
| Reicin Glenn | officer: CHIEF FINANCIAL OFFICER | 2026-04-14 | A-Award | 29.29 | 2026-05-18 |
| Reicin Glenn | 2026-04-14 | 0 | 2026-05-18 | ||
| Zaeske Adam H. | officer: CHIEF COMMERCIAL OFFICER | 2026-04-07 | M-Exempt | 0 | 2026-04-09 |
| Zaeske Adam H. | officer: CHIEF COMMERCIAL OFFICER | 2026-04-07 | M-Exempt | 0 | 2026-04-09 |
| Zaeske Adam H. | officer: CHIEF COMMERCIAL OFFICER | 2026-04-07 | F-InKind | 27.62 | 2026-04-09 |
| Anastasiou Peter | officer: CHIEF OPERATING OFFICER | 2026-04-02 | A-Award | 27.74 | 2026-04-06 |
| Ignelzi Troy A. | director | 2026-04-02 | A-Award | 27.74 | 2026-04-06 |
| Ignelzi Troy A. | 2026-04-02 | 0 | 2026-04-06 | ||
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2026-01-26 | S-Sale | 37.152 | 2026-01-28 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2026-01-22 | A-Award | 36.76 | 2026-01-26 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2026-01-25 | M-Exempt | 0 | 2026-01-26 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2026-01-22 | A-Award | 0 | 2026-01-26 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2026-01-24 | M-Exempt | 0 | 2026-01-26 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2026-01-25 | M-Exempt | 0 | 2026-01-26 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2026-01-24 | M-Exempt | 0 | 2026-01-26 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2026-01-25 | F-InKind | 36.82 | 2026-01-26 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2026-01-24 | F-InKind | 36.82 | 2026-01-26 |
| Serafin Andrew | officer: CHIEF STRATEGY OFFICER | 2026-01-22 | A-Award | 36.76 | 2026-01-26 |
| Serafin Andrew | officer: CHIEF STRATEGY OFFICER | 2026-01-22 | A-Award | 0 | 2026-01-26 |
| Serafin Andrew | officer: CHIEF STRATEGY OFFICER | 2026-01-25 | M-Exempt | 0 | 2026-01-26 |
| Serafin Andrew | officer: CHIEF STRATEGY OFFICER | 2026-01-24 | M-Exempt | 0 | 2026-01-26 |
| Serafin Andrew | officer: CHIEF STRATEGY OFFICER | 2026-01-25 | M-Exempt | 0 | 2026-01-26 |
| Serafin Andrew | officer: CHIEF STRATEGY OFFICER | 2026-01-24 | M-Exempt | 0 | 2026-01-26 |
| Serafin Andrew | officer: CHIEF STRATEGY OFFICER | 2026-01-25 | F-InKind | 36.82 | 2026-01-26 |
| Serafin Andrew | officer: CHIEF STRATEGY OFFICER | 2026-01-24 | F-InKind | 36.82 | 2026-01-26 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2026-01-22 | A-Award | 36.76 | 2026-01-26 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2026-01-22 | A-Award | 0 | 2026-01-26 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2026-01-25 | M-Exempt | 0 | 2026-01-26 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2026-01-24 | M-Exempt | 0 | 2026-01-26 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2026-01-25 | M-Exempt | 0 | 2026-01-26 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2026-01-24 | M-Exempt | 0 | 2026-01-26 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2026-01-25 | F-InKind | 36.82 | 2026-01-26 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2026-01-24 | F-InKind | 36.82 | 2026-01-26 |
| Zaeske Adam H. | officer: CHIEF COMMERCIAL OFFICER | 2026-01-22 | A-Award | 36.76 | 2026-01-26 |
| Zaeske Adam H. | officer: CHIEF COMMERCIAL OFFICER | 2026-01-22 | A-Award | 0 | 2026-01-26 |
| Dayno Jeffrey M. | director, officer: PRESIDENT, CEO | 2026-01-22 | A-Award | 36.76 | 2026-01-26 |
| Dayno Jeffrey M. | director, officer: PRESIDENT, CEO | 2026-01-22 | A-Award | 0 | 2026-01-26 |
| Dayno Jeffrey M. | director, officer: PRESIDENT, CEO | 2026-01-25 | M-Exempt | 0 | 2026-01-26 |
| Dayno Jeffrey M. | director, officer: PRESIDENT, CEO | 2026-01-24 | M-Exempt | 0 | 2026-01-26 |
| Dayno Jeffrey M. | director, officer: PRESIDENT, CEO | 2026-01-25 | M-Exempt | 0 | 2026-01-26 |
| Dayno Jeffrey M. | director, officer: PRESIDENT, CEO | 2026-01-24 | M-Exempt | 0 | 2026-01-26 |
| Dayno Jeffrey M. | director, officer: PRESIDENT, CEO | 2026-01-25 | F-InKind | 36.82 | 2026-01-26 |
| Dayno Jeffrey M. | director, officer: PRESIDENT, CEO | 2026-01-24 | F-InKind | 36.82 | 2026-01-26 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2026-01-15 | S-Sale | 35.9159 | 2026-01-20 |
| Dayno Jeffrey M. | director, officer: PRESIDENT, CEO | 2025-12-12 | M-Exempt | 8.22 | 2025-12-17 |
| Dayno Jeffrey M. | director, officer: PRESIDENT, CEO | 2025-12-12 | S-Sale | 40.1073 | 2025-12-17 |
| Dayno Jeffrey M. | director, officer: PRESIDENT, CEO | 2025-12-12 | M-Exempt | 8.22 | 2025-12-17 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2025-12-05 | M-Exempt | 29.03 | 2025-12-09 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2025-12-05 | M-Exempt | 29.03 | 2025-12-09 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2025-12-05 | S-Sale | 39.5448 | 2025-12-09 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2025-11-21 | S-Sale | 35 | 2025-11-25 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2025-09-30 | M-Exempt | 0 | 2025-10-02 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2025-09-30 | M-Exempt | 0 | 2025-10-02 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2025-09-30 | F-InKind | 27.56 | 2025-10-02 |
| Valor IV Pharma Holdings, LLC | 10 percent owner | 2025-08-28 | J-Other | 0 | 2025-09-02 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2025-08-15 | S-Sale | 36.4983 | 2025-08-19 |
| Sabater Juan A. | director | 2025-05-15 | A-Award | 34.23 | 2025-05-16 |
| Gracias Antonio J. | director | 2025-05-15 | A-Award | 34.23 | 2025-05-16 |
| Philip Ron M | director | 2025-05-15 | A-Award | 34.23 | 2025-05-16 |
| Szyper Linda M | director | 2025-05-15 | A-Award | 34.23 | 2025-05-16 |
| Anastasiou Peter | director | 2025-05-15 | A-Award | 34.23 | 2025-05-16 |
| Graf R. Mark | director | 2025-05-25 | A-Award | 34.23 | 2025-05-16 |
| Sender Gary | director | 2025-05-15 | A-Award | 34.23 | 2025-05-16 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2025-05-01 | M-Exempt | 0 | 2025-05-09 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2025-05-01 | M-Exempt | 0 | 2025-05-09 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2025-05-01 | F-InKind | 29.86 | 2025-05-09 |
| Zaeske Adam H. | officer: CHIEF COMMERCIAL OFFICER | 2025-04-07 | A-Award | 28.4 | 2025-04-16 |
| Zaeske Adam H. | officer: CHIEF COMMERCIAL OFFICER | 2025-04-07 | A-Award | 0 | 2025-04-16 |
| Zaeske Adam H. | 2025-04-07 | 0 | 2025-04-16 | ||
| Philip Ron M | director | 2025-04-02 | A-Award | 32.53 | 2025-04-04 |
| Philip Ron M | 2025-04-02 | 0 | 2025-04-04 | ||
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2025-04-01 | S-Sale | 32.4765 | 2025-04-03 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2025-04-01 | S-Sale | 33.1152 | 2025-04-03 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2025-03-29 | M-Exempt | 0 | 2025-04-01 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2025-03-29 | M-Exempt | 0 | 2025-04-01 |
| Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | 2025-03-29 | F-InKind | 33.19 | 2025-04-01 |
| Dierks Jeffrey | officer: CHIEF COMMERCIAL OFFICER | 2025-03-03 | M-Exempt | 8.22 | 2025-03-05 |
| Dierks Jeffrey | officer: CHIEF COMMERCIAL OFFICER | 2025-03-03 | S-Sale | 32.6103 | 2025-03-05 |
| Dierks Jeffrey | officer: CHIEF COMMERCIAL OFFICER | 2025-03-03 | S-Sale | 33.2302 | 2025-03-05 |
| Dierks Jeffrey | officer: CHIEF COMMERCIAL OFFICER | 2025-03-03 | M-Exempt | 8.22 | 2025-03-05 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2025-01-25 | A-Award | 38.01 | 2025-01-28 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2025-01-25 | A-Award | 0 | 2025-01-28 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2025-01-24 | M-Exempt | 0 | 2025-01-28 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2025-01-24 | M-Exempt | 0 | 2025-01-28 |
| Budur Kumar | officer: CHIEF MEDICAL OFFICER | 2025-01-24 | F-InKind | 38.01 | 2025-01-28 |
| Dierks Jeffrey | officer: CHIEF COMMERCIAL OFFICER | 2025-01-25 | A-Award | 38.01 | 2025-01-28 |
| Dierks Jeffrey | officer: CHIEF COMMERCIAL OFFICER | 2025-01-24 | M-Exempt | 30.69 | 2025-01-28 |
| Dierks Jeffrey | officer: CHIEF COMMERCIAL OFFICER | 2025-01-25 | A-Award | 0 | 2025-01-28 |
| Dierks Jeffrey | officer: CHIEF COMMERCIAL OFFICER | 2025-01-24 | M-Exempt | 30.69 | 2025-01-28 |
| Dierks Jeffrey | officer: CHIEF COMMERCIAL OFFICER | 2025-01-24 | M-Exempt | 0 | 2025-01-28 |